Cancer immunotherapy has emerged as a powerful treatment option characterized by durable remissions and tolerable side effects.
In recent years, an unprecedented number of immune-based therapeutic modalities have been approved in the first- and second-line as well as in the adjuvant setting across a growing number of malignancies. This influx of approvals has created a need to stay current on the latest recommendations for the appropriate application of immunotherapy.
SITC Cancer Immunotherapy CONNECT is your hub to participate in live and online educational opportunities to learn more about integrating cancer immunotherapy into your practice. Download a variety of resources in the SITC Resource Library and connect with other clinicians in the Cancer Immunotherapy CONNECT Open Forum to learn more about the latest approvals, patient selection criteria, relevant biomarkers and immune-related adverse events.
It was great seeing old friends again and meeting new ones at the 32 nd Annual Meeting & Pre-Conference Programs in National Harbor! We appreciate all who joined SITC for our most successful ...
The cited 2017 case report states " The restoration of the cellular immune response against tumor cells through PD-1 blockade and CRLA-4 blockade have recently been shown to be associated ...
This is an interesting subject to me since a few years back we published a study in the American Journal of Transplantation that showed blocking mTOR with a low dose of rapamycin enhanced ...
Thanks for the comments. He is to start TKI, but is also asking about other ideas. There are multiple non-Oncologist physicians in family who are feeding him questions and idea. I'm sure ...
View More Clinician Resources
In this video, hear SITC Annual Meeting delegates explain the purpose and benefits for joining thousands of their colleagues at the Annual Meeting & Pre-Conference Programs, share how far the science of cancer immunotherapy has progressed and predict where the field is headed. Also, learn about the benefits of becoming a member of SITC.
For more than 30 years SITC (Society for Immunotherapy of Cancer) has been fighting for treatment and a cure for cancer through research and collaboration. SITC members all over the world are leading the charge against cancer. We’re traveling the globe to meet these thought leaders and demonstrate the crucial work that they’re doing to impact advances in both the science and clinical application of immunotherapy.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org